Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice.
about
Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosisA Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral IschemiaImpacts of tissue-type plasminogen activator (tPA) on neuronal survivalPhysiological and pathological roles of tissue plasminogen activator and its inhibitor neuroserpin in the nervous systemTissue-type plasminogen activator is a neuroprotectant in the central nervous systemDelivery of drugs bound to erythrocytes: new avenues for an old intravascular carrierVascular protection to increase the safety of tissue plasminogen activator for strokeNeuroserpin Differentiates Between Forms of Tissue Type Plasminogen Activator via pH Dependent Deacylation.Deficiency in serine protease inhibitor neuroserpin exacerbates ischemic brain injury by increased postischemic inflammationConformations of tissue plasminogen activator (tPA) orchestrate neuronal survival by a crosstalk between EGFR and NMDAR.Minor inflammation after surgical evacuation compared with fibrinolytic therapy of experimental intracerebral hemorrhagesKey role of tissue plasminogen activator in neurovascular couplingRecombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-AnalysisRegulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independentMyocyte enhancer factor 2C as a neurogenic and antiapoptotic transcription factor in murine embryonic stem cellsMutant prourokinase with adjunctive C1-inhibitor is an effective and safer alternative to tPA in rat strokeThe serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptorsPharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular diseaseIdentification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin.α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancementsTargeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhageEffect of thrombolysis on the dynamics of infarct evolution after clot embolism of middle cerebral artery in mice.Tissue plasminogen activator protects hippocampal neurons from oxygen-glucose deprivation injury.Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model.Tissue plasminogen activator-induced ischemic injury is reversed by NMDA antagonist MK-801 in vivo.Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.Role of Transporters in Central Nervous System Drug Delivery and Blood-Brain Barrier Protection: Relevance to Treatment of StrokeRecombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in miceNovel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis.Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysisRed blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the nPlasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusionMolecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activatorHemostasis and alterations of the central nervous systemSerine protease inhibitors: novel therapeutic targets for stroke?Plasminogen activators promote excitotoxicity-induced retinal damage
P2860
Q24534050-0D3DB5CA-C1A7-4E9B-9767-1FE91709A2FDQ26772837-4AFD4151-3072-402A-B8A9-F417AD2F3F5CQ26777261-6DE1AAC0-3B54-46BD-BF2F-4F70C094229DQ26777276-CD896867-6A86-4E0C-BD2E-965F898F427EQ26782904-391D033C-CD4A-432B-8B82-6D1F19F56EEEQ26801300-EEF699F1-7210-4E79-A5B9-A77B46D6212DQ26824338-923AA871-F3DC-4BF4-8D42-4755AD6CD74CQ27319705-0E1713FA-6B40-4320-85B4-4B60A95AF421Q27321143-5242DD06-67D2-40E9-B3E2-FBF06FD02E24Q27329809-FC7D0A4E-3FB7-4417-BBD4-F2517C9BEFAAQ28181833-B63FD952-6F38-48CD-90D0-F1BD00CAB715Q28512912-753D4277-D5C9-48C5-AC6E-B18B437AA54BQ28552445-A9D36D41-4106-4409-9E2C-9525BCD337DEQ28584148-5729F357-CE40-41C1-A888-92892F596DF2Q28591351-D098691A-464B-47D6-A862-EDF4E6BF752DQ28742609-1FCA5804-05BD-41DE-BF8E-4263FCB2BE79Q28771352-4C5A2F01-8F18-47C7-8E5F-A62ED133CB6FQ29243373-893B55A9-DED8-4B89-8B95-21597208F332Q29465533-53B3152B-9D25-4876-8614-FA991C87CEF3Q30248728-A9EF647D-426E-4547-BCE0-61040ECBF320Q30393215-7A977E39-E129-41AA-AE46-8E53B4DDFF49Q30747694-675FE0A3-7020-47E0-AD3C-ADAB5832E593Q30948637-B14F672C-0782-48BB-AB18-8C009F6F06A2Q32063592-984A225D-FB54-4B81-886C-DFF6162717B4Q33217880-79B11DC2-B431-41B0-9C96-FD7D16D5D5A4Q33253908-0F4A97C2-E359-4EA9-BB79-3E6B6E1CFC05Q33369942-668AE10C-AA8D-4D07-9008-F0AE33948A72Q33504867-01C246A6-AA1F-472B-A06E-91D8BD34AB56Q33565967-60971920-A2BB-48D9-ACD2-CEB83ABE062AQ33581243-7C6D5C91-A443-4813-84F2-258EC388E360Q33600876-39ECF39D-C272-46E7-863E-C886EE79BCD7Q33610598-69981F35-E423-4DCF-A84D-4420397B73A1Q33696788-7E2DD15D-E260-4897-AEA0-CF6D762FDF34Q33714889-B63A3B82-797E-4A8F-A122-B5AABAD79457Q33734359-9294A008-11A8-4BF9-9BEF-3442CBA8197BQ33767438-870B44B3-E1F5-4146-8C8D-03DA0079DF5DQ33823616-574314AF-3B68-42C5-B32C-D020265953FCQ33842161-570A564A-C89C-4593-9AF2-D1416B32C248Q33926785-AC18D7C9-B38A-4473-81A0-899F13327256Q33946252-D6185740-D65C-4393-9316-D8802AF96BBA
P2860
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Tissue plasminogen activator ( ...... d-type and tPA-deficient mice.
@en
type
label
Tissue plasminogen activator ( ...... d-type and tPA-deficient mice.
@en
prefLabel
Tissue plasminogen activator ( ...... d-type and tPA-deficient mice.
@en
P2093
P356
P1433
P1476
Tissue plasminogen activator ( ...... d-type and tPA-deficient mice.
@en
P2093
P2888
P304
P356
10.1038/NM0298-228
P407
P577
1998-02-01T00:00:00Z